172 related articles for article (PubMed ID: 24359601)
1. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
Jørgensen CL; Nielsen TO; Bjerre KD; Liu S; Wallden B; Balslev E; Nielsen DL; Ejlertsen B
Acta Oncol; 2014 Jun; 53(6):776-87. PubMed ID: 24359601
[TBL] [Abstract][Full Text] [Related]
2. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Jørgensen CL; Bjerre C; Ejlertsen B; Bjerre KD; Balslev E; Bartels A; Brünner N; Nielsen DL
BMC Cancer; 2014 May; 14():360. PubMed ID: 24884504
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Nielsen DL; Bjerre KD; Jakobsen EH; Cold S; Stenbygaard L; Sørensen PG; Kamby C; Møller S; Jørgensen CL; Andersson M
J Clin Oncol; 2011 Dec; 29(36):4748-54. PubMed ID: 22084374
[TBL] [Abstract][Full Text] [Related]
4. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Jørgensen CL; Ejlertsen B; Bjerre KD; Balslev E; Nielsen DL; Nielsen KV
BMC Cancer; 2013 Nov; 13():541. PubMed ID: 24215511
[TBL] [Abstract][Full Text] [Related]
5. The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.
Stovgaard ES; Asleh K; Riaz N; Leung S; Gao D; Nielsen LB; Lænkholm AV; Balslev E; Jensen MB; Nielsen D; Nielsen TO
Oncoimmunology; 2021 May; 10(1):1924492. PubMed ID: 34026336
[TBL] [Abstract][Full Text] [Related]
6. Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.
Asleh K; Lyck Carstensen S; Tykjaer Jørgensen CL; Burugu S; Gao D; Won JR; Jensen MB; Balslev E; Laenkholm AV; Nielsen DL; Ejlertsen B; Nielsen TO
Int J Cancer; 2019 May; 144(10):2578-2586. PubMed ID: 30411790
[TBL] [Abstract][Full Text] [Related]
7. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Seidman AD; Brufsky A; Ansari RH; Hart LL; Stein RS; Schwartzberg LS; Stewart JF; Russell CA; Chen SC; Fein LE; De La Cruz Vargas JA; Kim SB; Cavalheiro J; Zhao L; Gill JF; Obasaju CK; Orlando M; Tai DF
Ann Oncol; 2011 May; 22(5):1094-1101. PubMed ID: 21084429
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
11. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
12. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Seidman AD; Chan S; Wang J; Zhu C; Xu C; Xu B
Oncologist; 2014 May; 19(5):443-52. PubMed ID: 24705980
[TBL] [Abstract][Full Text] [Related]
14. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG).
Tomova A; Bartsch R; Brodowicz T; Tzekova V; Timcheva C; Wiltschke C; Gerges DA; Pawlega J; Spanik S; Inbar M; Zielinski CC
Breast Cancer Res Treat; 2010 Jan; 119(1):169-76. PubMed ID: 19768533
[TBL] [Abstract][Full Text] [Related]
15. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Joensuu H; Sailas L; Alanko T; Sunela K; Huuhtanen R; Utriainen M; Kokko R; Bono P; Wigren T; Pyrhönen S; Turpeenniemi-Hujanen T; Asola R; Leinonen M; Hahka-Kemppinen M; Kellokumpu-Lehtinen P
Ann Oncol; 2010 May; 21(5):968-73. PubMed ID: 19819914
[TBL] [Abstract][Full Text] [Related]
17. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Del Mastro L; Fabi A; Mansutti M; De Laurentiis M; Durando A; Merlo DF; Bruzzi P; La Torre I; Ceccarelli M; Kazeem G; Marchi P; Boy D; Venturini M; De Placido S; Cognetti F
BMC Cancer; 2013 Mar; 13():164. PubMed ID: 23537313
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
19. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Nielsen TO; Parker JS; Leung S; Voduc D; Ebbert M; Vickery T; Davies SR; Snider J; Stijleman IJ; Reed J; Cheang MC; Mardis ER; Perou CM; Bernard PS; Ellis MJ
Clin Cancer Res; 2010 Nov; 16(21):5222-32. PubMed ID: 20837693
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Jeong JH; Jung SY; Park IH; Lee KS; Kang HS; Kim SW; Kwon Y; Kim EA; Ko KL; Nam BH; Lee S; Ro J
Invest New Drugs; 2012 Feb; 30(1):408-16. PubMed ID: 20922557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
